. Estimated association between vitamin D levels and odds of organ-specific lupus disease activity, adjusting for age, race, sex, calendar year, prednisone use and plaquenil use Vitamin D Level (ng/mL) Immunologic Disease Skin Disease Renal Disease Activity Activity Activity OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value <10 (n=163) 1.0 (0.7, 1.5) 0.88 1.4 (1.0, 2.1) 0.049 3.1 (2.0, 4.9) <0.0001 10-20 (n=1039) 1.0 (0.9, 1.1) 0.93 0.9 (0.8, 1.1) 0.41 2.2 (1.5, 3.1) <0.0001 20-30 (n=2760) 1.0 (0.9, 1.1) 0.97 1.0 (0.9, 1.2) 0.53 1.6 (1.2, 2.0) 0.0008 30-40 (n=3959) 1.0 (0.9, 1.1) 0.78 1.1 (1.0, 1.2) 0.13 1.2 (0.9, 1.5) 0.23 40-50 (n=3578) 1 However, for skin activity, there was a significantly elevated risk among those in the very extreme levels of vitamin D. For Renal Disease Activity, there was a significantly higher rate of renal disease activity among those with low levels of vitamin D. In addition, there was a clear trend such that the higher the vitamin D, the lower the risk of renal disease activity. We then conducted a "within person" analysis. In this analysis, each person serves as his own control, and the question is: "When a person has a vitamin D level lower than his/her average, are they more likely to have renal disease activity". Note, this analysis implicitly adjusts for race, sex, and all variables (measured and unmeasured) that are invariant within a person. The results are shown in Table 2 . 
Background:
The benefit of vitamin D on SLE global and renal activity have now been proven by both cohort studies and a clinical trial. The benefits on cardiovascular risk factors, however, are less well understood. Objectives: We present the first longitudinal study on hyperlipidemia. Methods: A within-person aanalysis addressed the question of whether a person tends to have higher cholesterol when her vitamin D is lower than her average vitamin D. To assess this, for each visit, we calculated the difference between the vitamin D level at that visit and the person's average of vitamin D. Differences in the range of vitamin D <50 ng/mL were distinguished from differences in the range above 50 ng/mL. Then we modelled the relationship between these differences in vitamin D and the difference between the person's cholesterol at each visit and the person's average cholesterol. Results: P-value 0-50 ng/mL -3.4 (-3.9, -2.9) <0.0001 -3.1 (-3.6, -2.6) <0.0001 50+ ng/mL -1.1 (-1.7, -0.5) 0.0003 -1.0 (-1.7, -0.4) 0.0016 Background: Therapeutic plasma exchange (TPE) offers an alternative therapeutic modality for patients with systemic lupus erythematosus (SLE) and primary antiphospholipid syndrome (APS). However, there is conflicting evidence regarding its efficacy in different sub-phenotypes. Objectives: This study aims to investigate the main clinical characteristics and outcomes of patients with different phenotypes of SLE and APS treated with TPE at a tertiary care centre. Methods: Database of Blood and Apheresis Unit between 2001-2013 was screened for patients with SLE and primary APS. SLE disease activity index (SELENA-SLEDAI), the indications for treatment, complications and outcomes were obtained from review of medical records and phone calls. A total of 24 patients (SLE: 20, APS: 4) were recruited for the study.
Results: Mean ages of SLE (M/F: 1/19) and primary APS (PAPS) patients (M/F:
2/2) were 32.4±12.89 and 52.0±10.7, respectively. The main indications for TPE were haematologic, neurologic, pulmonary involvement and APS-related. TPE was preferred in 8 patients because of leukopenia, and co-infection. SLEDAI was significantly decreased after TPE (16.7±8.3 vs. 8.8±3.1, p=0.001). Both primary APS and SLE related CAPS patients had completely responded to TPE. Success rate of TPE in patients with thrombocytopenia were lower than patients with haemolytic anaemia. Median (IQR 25%>75%) TPE sessions were 6.5 (5-10.5). Background: Azathioprine (AZA) is a common treatment for connective tissue diseases (CTD). AZA is a pro-drug which is metabolised to active moieties of 6-thioguanine (6-TGN) and 6-methylmercaptopurine (6-MMP). These metabolites, rather than the absolute dose of AZA, are associated with clinical efficacy and toxicity. An idiosyncratic skewed metabolism towards 6-MMP in some patients ("shunters") increases the risk of hepatotoxicity and treatment failure. Allopurinol can correct such shunts 1 . Therapeutic protocols using metabolite concentrations have been shown to be cost effective, improve efficacy, and decrease treatment morbidity in IBD 1 . Only one small study estimated a therapeutic 6-TGN level for SLE patients 2 . There are scant data on AZA shunters in connective tissue disease 3 . Objectives: Explore the proportion of AZA therapeutic failure, toxicity, and shunters in CTD patients. Methods: Retrospective, multicentre audit of AZA metabolite levels in CTD patients from 2012-2016. Patient demographics, treatments, disease activity and drug toxicity were also extracted. Results: 61 testing episodes occurred in 34 patients whose mean age was 55 (32-79) years; predominantly female (N=26, 77%), with SLE (N=19, 56%). Active disease was present in 15/61 (25%) episodes. 20/34 (60%) patients were on HCQ + AZA. 25/34 (76%) of patients were either on no or <10mg/day of prednisone. 22/61 (36%) episodes had bone marrow suppression, and 8/61 (13%) had moderate liver function derangement. 12/35 (34%) patients were AZA shunters. Based on AZA metabolite levels, patients were classified into four categories: SLE patients were over-represented in the underdosed/non-compliant category (7/9). Patients in underdosed and 6-MMP shunter categories had more active disease (44% & 31%), compared with appropriate and overdosed (17% and 19% p=0.24) . Surprisingly, patients who were overdosed by 6TGN levels had the lowest mean AZA dose. 6-MMP shunters had significantly lower median 6TGN levels (147pmol/8x10 8 RBC), yet toxic MMP levels (9630pmol/8x10 8 RBC) that was associated with worst LFT derangement prevalence (4/13, 31% vs <13%, p=0.16). Conclusions: AZA dose is poorly predictive of 6-TGN and 6-MMP levels. Overall, one third of CTD patients were shunters, with lower 6-TGN levels and more hepatotoxicity. Only 40% of test episodes were appropriately dosed. Patients with low disease activity are more likely to have adequate 6TGN levels, however, 40% of patients with CTD won't have adequate disease control despite therapeutic 6-TGN levels. AZA metabolites can identify the multiple causes for therapeutic failure (under dosing, shunter, or true non-response), and enable early detection of shunters to avoid liver toxicity. Background: Hydroxychloroquine (HCQ) are considered to be effective against cutaneous lupus erythematosus (CLE) and symptoms associated with systemic lupus erythematosus (SLE) such as rashes, joint pain, and fatigue. In a randomized controlled trial in stable active patients with SLE on HCQ treatment, those who achieved blood HCQ levels greater than or equal to 1000ng/ml had a tendency for reduced SLE flares during a 7 month period [1] . To prevent ocular toxicity, HCQ should be maintained at a dose of 6.5mg/kg or less for ideal body weight [2] , however, optimal HCQ dosage is unclear. Objectives: To extract the problem of the dosage based on ideal body weight and identify safer and more effective HCQ dosage. Methods: We enrolled patients who took HCQ for SLE or CLE more than 3 months in our institute and 2 related facilities from September 2015. We used Cutaneous Lupus Erythematous Disease Area and Severity Index (CLASI) to evaluate cutaneous symptoms and evaluated effect at start of administration and 3 months of that. The attending doctors assessed the adverse events (AEs). We investigated the change of serum biomarker, such as the value of serum
